Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan, TAS-102, and Bevacizumab in Refractory mCRC
NCT06403709Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Aug 2022; status: active, not recruiting.
02
Drugs
trifluridine + tipiracilirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabbevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06403709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06403709.